Literature DB >> 6502174

The treatment of severe dystonia in children and adults.

C D Marsden, M H Marion, N Quinn.   

Abstract

Twenty-three children (aged less than 18 years) and 17 adults with severe widespread dystonia were treated with high doses of benzhexol (up to 130 mg daily introduced slowly over many weeks). Children tolerated higher doses (median 30 mg/day) than adults (median 20 mg/day). 52% of the children gained useful benefit, many (43%) without unwanted side effects. Such an approach was less successful in adults; 41% gained benefit, but only 35% had no side effects. Twelve adults with severe axial dystonia, and two children with life-threatening generalised dystonia were treated with a combination of a low constant dose of tetrabenazine to which were added pimozide and benzhexol as necessary. The dose of tetrabenazine was aimed at 75 mg daily; pimozide was increased (6 to 25 mg/day) until the dystonia was relieved or Parkinsonism and other side-effects prevented further increments; if necessary benzhexol (6 to 30 mg/day) then was added to control side-effects and to provide additional benefit. 75% of the adults with severe axial dystonia, and one of the two children with life threatening generalised dystonia gained useful benefit from this regime. It is concluded that high dose benzhexol is the present first treatment of choice for children with severe dystonia, and is worth a try in adults but with less expectation of success. When benzhexol treatment alone fails in adults with severe disabling axial dystonia, or in children with life-threatening generalised dystonia, combined therapy with tetrabenazine, pimozide and benzhexol may give valuable symptomatic relief.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6502174      PMCID: PMC1028082          DOI: 10.1136/jnnp.47.11.1166

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  14 in total

1.  Neurochemical changes following the administration of depleters of biogenic monoamines.

Authors:  J D Lane; J E Smith; P A Shea; W J McBride
Journal:  Life Sci       Date:  1976-12-01       Impact factor: 5.037

2.  Treatment of involuntary movement disorders with tetrabenazine.

Authors:  M Swash; A H Roberts; H Zakko; K W Heathfield
Journal:  J Neurol Neurosurg Psychiatry       Date:  1972-04       Impact factor: 10.154

3.  Combined nitoman-pimozide treatment of Huntington's chorea and other hyperkinetic syndromes.

Authors:  R Fog; H Pakkenberg
Journal:  Acta Neurol Scand       Date:  1970       Impact factor: 3.209

4.  Delayed-onset dystonia in patients with "static" encephalopathy.

Authors:  R E Burke; S Fahn; A P Gold
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-09       Impact factor: 10.154

5.  Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study.

Authors:  J Jankovic
Journal:  Ann Neurol       Date:  1982-01       Impact factor: 10.422

6.  Production of catalepsy and depletion of brain monoamines by a butyrophenone derivative.

Authors:  L D Fuenmayor; M Vogt
Journal:  Br J Pharmacol       Date:  1979-09       Impact factor: 8.739

Review 7.  Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry.

Authors:  R M Pinder; R N Brogden; R Swayer; T M Speight; R Spencer; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

8.  Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue.

Authors:  E K Perry; P H Gibson; G Blessed; R H Perry; B E Tomlinson
Journal:  J Neurol Sci       Date:  1977-11       Impact factor: 3.181

9.  Writers' cramp-a focal dystonia.

Authors:  M P Sheehy; C D Marsden
Journal:  Brain       Date:  1982-09       Impact factor: 13.501

10.  An analysis of the learning deficit following hyoscine administration to man.

Authors:  T J Crow; I G Grove-White
Journal:  Br J Pharmacol       Date:  1973-10       Impact factor: 8.739

View more
  21 in total

1.  Benztropine for acute muscle spasm in the emergency department.

Authors:  N L Epstein
Journal:  CMAJ       Date:  2001-01-23       Impact factor: 8.262

Review 2.  Current and emerging strategies for treatment of childhood dystonia.

Authors:  Matteo Bertucco; Terence D Sanger
Journal:  J Hand Ther       Date:  2014-11-15       Impact factor: 1.950

3.  The pharmacological characterisation of pilocarpine-induced purposeless chewing behaviour in the rat.

Authors:  B R Stewart; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 4.  Nonmotor manifestations of dystonia: a systematic review.

Authors:  Daniel J Kuyper; Veronica Parra; Shanae Aerts; Michael S Okun; Benzi M Kluger
Journal:  Mov Disord       Date:  2011-04-11       Impact factor: 10.338

5.  Stridor during dystonic phases of Parkinson's disease.

Authors:  D O Corbin; A C Williams
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-06       Impact factor: 10.154

6.  Successful treatment of refractory Sydenham's chorea with pimozide.

Authors:  R Harries-Jones; J G Gibson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-04       Impact factor: 10.154

7.  Strategies for treatment of dystonia.

Authors:  Dirk Dressler; Eckart Altenmueller; Roongroj Bhidayasiri; Saeed Bohlega; Pedro Chana; Tae Mo Chung; Steven Frucht; Pedro J Garcia-Ruiz; Alain Kaelin; Ryuji Kaji; Petr Kanovsky; Rainer Laskawi; Federico Micheli; Olga Orlova; Maja Relja; Raymond Rosales; Jaroslaw Slawek; Sofia Timerbaeva; Thomas T Warner; Fereshte Adib Saberi
Journal:  J Neural Transm (Vienna)       Date:  2015-09-14       Impact factor: 3.575

Review 8.  Movement disorder emergencies.

Authors:  Kathleen L Poston; Steven J Frucht
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

9.  EMG biofeedback treatment of torticollis: a controlled outcome study.

Authors:  M Jahanshahi; G Sartory; C D Marsden
Journal:  Biofeedback Self Regul       Date:  1991-12

Review 10.  Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation.

Authors:  Ian O Bledsoe; Aaron C Viser; Marta San Luciano
Journal:  Neurotherapeutics       Date:  2020-10-23       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.